Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.
Feb 10, 2022
0
11
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumor. ...
Feb 9, 2022
0
40
The risk of death for patients with SARS-CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published in the Journal of Thoracic Oncology, the official journal of the International ...
Feb 1, 2022
0
7
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, ...
Jan 17, 2022
0
75
Patients with lung cancer who quit smoking after their diagnosis have a 29 percent improvement in their overall survival compared to patients who continue smoking after diagnosis, according to a study published in the Journal ...
Jan 4, 2022
0
23
To diagnose lung cancer, tumor tissue is collected from a patient and checked for signs of cancer. However, this is not always possible due to tumor location, and can be painful for the patient. For his Ph.D. research, Remco ...
Dec 14, 2021
0
1
In the past decade, immunotherapy has helped save the lives of many cancer patients, many with lung cancer, who might have otherwise faced almost certain death sentences. However, only about 20% of patients who received immune ...
Dec 9, 2021
0
138
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors. The ...
Nov 24, 2021
0
1360
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers ...
Nov 9, 2021
0
67
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset ...
Oct 29, 2021
0
83
